Ratio Based Biomarkers for the Prediction of Cancer Survival
The AKT pathway plays a key role in the regulation of cellular survival, apoptosis, and protein translation and has been shown to have prognostic significance in a number of cancers. Recently, the inventors have identified several functions of the AKT pathway in certain cancers, such as extrahepatic cholangiocarcinoma (EHCC).
The NCI seeks partners to license or co-develop this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer. Utilizing multiplex tissue immunoblotting, the inventors have demonstrated that PTEN expression, PTEN/p-AKT ratios, and PTEN/p-mTOR ratios can predict the survival of cancer patients. These biomarkers may provide useful diagnostic information for cancer patients as well as identify patients appropriate for mTOR analog-based chemotherapy or agents directed against AKT.
Competitive Advantages:
- Useful to predict cancer patient survival
Commercial Applications:
- Diagnostic and Prognostic tool to detect the presence of cancer and predict the relative cancer survival rate for a subject with cancer
- Method of identifying patients appropriate for therapies targeted to the AKT pathway
- A kit for detecting cancer associated proteins in a sample
Patents
- US
Provisional (PRV) 61/144,501
Filed on 2009-01-14
Status: Abandoned - Patent Cooperation Treaty
(PCT) PCT/US2010/020944
Filed on 2010-01-13
Status: Expired - US
National Stage 13/144,474
Filed on 2011-07-13
Status: Abandoned - Australia
National Stage 2010204741
Filed on 2010-01-13
Status: Issued - Canada
National Stage 2749601
Filed on 2014-11-19
Status: Issued - European Patent
National Stage 10700363.4
Filed on 2010-01-13
Status: Issued - Israel
National Stage 214046
Filed on 2011-07-12
Status: Issued - Japan
National Stage 2011-545543
Filed on 2010-01-13
Status: Issued - New Zealand
National Stage 593514
Filed on 2011-06-16
Status: Issued - New Zealand
Divisional (DIV) 606687
Filed on 2013-02-05
Status: Issued - European Patent
Divisional (DIV) 13180742.2
Filed on 2010-01-13
Status: Abandoned - European Patent
Divisional (DIV) 13180760.4
Filed on 2010-01-13
Status: Issued - Germany
European patent (EP) 10700363.4
Filed on 2010-01-13
Status: Issued - France
European patent (EP) 10700363.4
Filed on 2010-01-13
Status: Issued - United Kingdom
European patent (EP) 10700363.4
Filed on 2010-01-13
Status: Issued - Japan
Divisional (DIV) 2013-247548
Filed on 2013-11-29
Status: Abandoned - New Zealand
Divisional (DIV) 624816
Filed on 2014-05-12
Status: Issued - Israel
Divisional (DIV) 233095
Filed on 2014-06-12
Status: Issued - Israel
Divisional (DIV) 233096
Filed on 2014-06-12
Status: Issued - Israel
Divisional (DIV) 233097
Filed on 2014-06-12
Status: Issued - Israel
Divisional (DIV) 233098
Filed on 2014-06-12
Status: Issued - New Zealand
Divisional (DIV) 628463
Filed on 2014-08-08
Status: Issued - Japan
Divisional (DIV) 2015-241016
Filed on 2010-01-13
Status: Issued - Australia
Divisional (DIV) 2016202107
Filed on 2016-04-05
Status: Issued - Germany
European patent (EP) 13180760.4
Filed on 2013-08-16
Status: Issued - France
European patent (EP) 13180760.4
Filed on 2013-08-16
Status: Issued - United Kingdom
European patent (EP) 13180760.4
Filed on 2013-08-16
Status: Issued - US
Continuation (CON) 15/349,991
Filed on 2016-11-11
Status: Abandoned - US Patent 11,237,169
Filed on 2018-12-12
Status: Issued - US
Continuation